Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Idenix Tumbles on HIV Setback

By Pharmaceutical Processing | February 11, 2011

NEW YORK
(AP) — Shares of Idenix Pharmaceuticals Inc. plunged after the company said federal regulators have temporarily halted
studies of an HIV and AIDS drug that the company developed.

Late Wednesday, Idenix said it was informed by its partner
ViiV Healthcare that the Food and Drug Administration placed a clinical hold on
studies of the drug. It did not disclose reasons for the clinical hold, which
prevents further human testing of the drug until the unspecified problem is
resolved. ViiV Healthcare was running a mid-stage clinical trial of the drug
candidate.

Shares of Idenix dropped $1.01, or 25.2 percent, to $3 in
premarket trading. The stock closed at $4.01 Wednesday and has traded between
$2.57 and $6.11 over the last year.

The drug is designated GSK2248761. ViiV Healthcare licensed
the product from Idenix in early 2009, and it is responsible for all clinical
development. ViiV Healthcare is a partnership between GlaxoSmithKline PLC and
Pfizer Inc. that focuses on HIV and AIDS drugs.

Idenix also said it expects to resume clinical testing of a
potential hepatitis C drug called IDX184 in the second half of 2011. The FDA
stopped trials of IDX184 in September because some healthy patients who were
treated with the drug and another Idenix drug, IDX320, experienced elevated
levels of liver enzymes. The FDA now has a partial clinical hold on IDX184. The
upcoming study will be a mid-stage trial evaluating IDX184 and two standard
hepatitis C therapies.

The Cambridge,
Mass., company said it is
discontinuing development of IDX320 because it believes that drug was
responsible for the side effect.

Oppenheimer
& Co. analyst Bret Holley said the HIV drug is “critical” to the
value of Idenix’s stock. He downgraded the shares to “Perform” from
“Outperform,” and removed his price target of $5 per share. The
developments for the hepatitis C drugs are good news, Holley wrote, but since
additional news on IDX184 is not likely to come until the end of the year, it
is unlikely the stock will trade much higher.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE